aluated the impact of adding bevacizumab to FOLFIRI and mIFL. A statistically significant improvement in OS for patients treated with FOLFIRI plus bevacizumab was seen when compared with those receiving mIFL plus bevacizumab. A total of 87 percent of patients were still alive after one year compared to 61 percent of patients given mIFL plus bevacizumab. The most frequent grade 3/4 adverse events in both arms were diarrhea, neutropenia and hypertension, with neutropenia and hypertension being higher in the FOLFIRI plus bevacizumab arm.

"This study enhances our understanding of combining FOLFIRI with the targeted agent bevacizumab as a standard treatment in first-line metastatic colorectal cancer patients," said Dr. Fuchs. "FOLFIRI plus bevacizumab significantly improved OS when compared to mIFL plus bevacizumab and both regimens were tolerable."

'"/>

Contact: Rachel Leopold
rachel.leopold@edelman.com
212-704-4433
Edelman Public Relations
5-Jun-2006

Page: 1 2
Related medicine news :

1. Study shows radiofrequency ablation highly effective in treating kidney tumors
2. Tumor cell activity may provide clues for treating breast cancer in young women
3. Mouse model points to possible new strategy for treating rare muscle disease, kidney disorders
4. Help for pediatricians in treating behavioral health problems only partially successful
5. ECP may be effective in treating Crohns disease
6. New guideline for treating Lyme disease
7. Certain combination therapy found more effective for treating malaria in African children
8. Article outlines current recommendations for treating malaria in the US
9. One pill may be better than two for treating patients with high blood pressure
10. Effectiveness of first renin inhibitor drug for treating hypertension is limited
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer